ArticleNon-coding RNA research2026
CircSMAD4 shapes matrix-remodeling TAMs in lung adenocarcinoma.
Article in Non-coding RNA research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung adenocarcinoma (LUAD) progression is strongly shaped by tumor-associated macrophages (TAMs), yet the post-transcriptional mechanisms that sustain matrix-remodeling TAM states remain incompletely understood. Here, circRNA profiling of LUAD TAMs versus normal tissue-resident macrophages identified circSMAD4 (hsa_circ_0047713) as a consistently TAM-enriched circRNA associated with advanced clinicopathological features and unfavorable survival. circSMAD4 exhibited canonical circular properties, including a validated back-splice junction, RNase R resistance, and enhanced transcript stability. Functionally, circSMAD4 knockdown in human and murine macrophages attenuated tumor education, shifted macrophages away from an M2-like phenotype, and weakened their ability to promote LUAD-cell proliferation, invasion, and EMT-like changes in co-culture. In syngeneic orthotopic lung and experimental metastasis models, circSMAD4-depleted macrophages restrained tumor growth and reduced metastatic burden. Mechanistically, cytoplasmic circSMAD4 acted as a ceRNA to sequester miR-562 and relieve repression of COL4A1. In parallel, circSMAD4 formed a specific ribonucleoprotein complex with the m6A reader IGF2BP2, facilitating IGF2BP2 association with COL4A1, ACTA2, and SPI1 transcripts and enhancing their m6A-dependent stability. Together, these dual branches converge on a matrix-remodeling output, positioning circSMAD4 as a post-transcriptional hub that reinforces protumor TAM programs in LUAD and a potential target for microenvironment-directed therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.